These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Boyle P; Gould AL; Roehrborn CG Urology; 1996 Sep; 48(3):398-405. PubMed ID: 8804493 [TBL] [Abstract][Full Text] [Related]
3. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Marberger MJ Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579 [TBL] [Abstract][Full Text] [Related]
4. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354 [TBL] [Abstract][Full Text] [Related]
5. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. Wilt TJ; Ishani A; Stark G; MacDonald R; Lau J; Mulrow C JAMA; 1998 Nov; 280(18):1604-9. PubMed ID: 9820264 [TBL] [Abstract][Full Text] [Related]
6. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Wilt TJ; Howe W; MacDonald R BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101 [TBL] [Abstract][Full Text] [Related]
7. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group. Grino P; Stoner E Eur Urol; 1994; 25 Suppl 1():24-8. PubMed ID: 7507052 [TBL] [Abstract][Full Text] [Related]
8. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111 [TBL] [Abstract][Full Text] [Related]
9. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. Edwards JE; Moore RA BMC Urol; 2002 Dec; 2():14. PubMed ID: 12477383 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J; Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309 [TBL] [Abstract][Full Text] [Related]
11. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia. Ekman P Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. Yu HJ; Chiu TY; Lai MK J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109 [TBL] [Abstract][Full Text] [Related]
14. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609 [TBL] [Abstract][Full Text] [Related]
15. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. MacDonald R; Wilt TJ; Howe RW BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102 [TBL] [Abstract][Full Text] [Related]
16. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291 [TBL] [Abstract][Full Text] [Related]
18. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762 [TBL] [Abstract][Full Text] [Related]
19. 5alpha-reductase inhibitors: what role should they play? Kaplan SA Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255 [TBL] [Abstract][Full Text] [Related]
20. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J; J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]